7-OH and Opioid Use Disorder: What Nurses Should Know

Last verified: October 2026 · Educational information only, not medical or legal advice

In an emergency (trouble breathing, unresponsive, seizure): call 911 and give naloxone if you have it. For suspected poisoning or an adverse reaction, call Poison Help at 1-800-222-1222. For crisis support, call or text 988.

Key points

7-hydroxymitragynine (7-OH) is a potent opioid. The FDA calls it an emerging public health threat.
Concentrated 7-OH products are not the same as kratom leaf. Leaf contains only trace amounts of 7-OH, while many products now sold are concentrated or synthesized.
Patients may not identify as opioid users and may not mention a "supplement" unless you ask.
Stopping can cause opioid-type withdrawal. Standard OUD medications are the usual starting point, but evidence specific to 7-OH is still limited.
In California, selling or manufacturing kratom and 7-OH products for consumption is prohibited.

What 7-OH is, and why it is a problem

7-OH is a compound found in tiny amounts in the kratom plant. Newer products are made by concentrating or chemically converting it, then selling it as tablets, gummies, shots or vapes, often in ordinary retail stores and without clear labeling. Clinicians describe it as acting on the same receptor as morphine and as far more potent than the leaf.

That combination makes dependence easy to develop and hard to recognize. People often start with a product they think of as a natural supplement, then find they cannot stop.

Dependence and withdrawal

Patients stopping concentrated 7-OH have reported opioid-type withdrawal: sweating, chills, anxiety, restlessness, muscle aches, nausea and vomiting, diarrhea and insomnia. Some use again mainly to relieve symptoms. There is a risk that people who cannot get 7-OH switch to other opioids, including illicit supplies that may contain fentanyl.

Medication management

There is no medication approved specifically for 7-OH dependence. Clinicians generally treat it like other opioid use disorder (OUD), using the same evidence-based tools:

Buprenorphine (including buprenorphine-naloxone), a partial opioid agonist used to relieve withdrawal and cravings.
Methadone, available through certified opioid treatment programs.
Supervised withdrawal management, with symptom-targeted medications and monitoring, ideally followed by longer-term treatment. Withdrawal management alone often leads to relapse.
Naltrexone after detoxification, for appropriate patients.

Prescribing is done by physicians and by NPs and PAs with the required registration and authority. Timing of the first buprenorphine dose, the dose, and what to do about the patient's other substances should come from a prescriber working from current guidance, since the research on 7-OH specifically is still developing. For the RN versus NP prescribing picture in California, see Psych RN vs. PMHNP scope of practice.

What nurses can do

Ask directly and without judgment. Include "kratom," "7-OH," "tianeptine" and "gas station supplements" in substance use screening, not only prescription and street opioids.
Look at the product. Ask the patient to show the package or photo. Document the product, amount, frequency and last use.
Screen for co-use and risk. Alcohol, benzodiazepines, other opioids and stimulants raise overdose risk. Ask about mental health symptoms and suicidality.
Know what withdrawal looks like. Use a validated opioid withdrawal scale your facility already uses, and escalate to the prescriber early.
Offer naloxone and linkage. Hand out naloxone, give the SAMHSA National Helpline (1-800-662-4357) and arrange follow-up before discharge.
Report adverse events. The FDA asks clinicians and the public to report them through MedWatch.

Legal status

California: The state health department says it is illegal to manufacture or sell kratom or 7-OH products for consumption. Enforcement began with product seizures and consumer warnings in late 2025, followed by Alcoholic Beverage Control enforcement visits to licensed businesses in early 2026.
Federal: In July 2026 the DEA announced its intent to temporarily place 7-OH above a set concentration threshold in Schedule I. The notice sets the threshold at more than 0.050 percent 7-OH (dry weight for plant material), or for processed products, more than 1.00 mg of 7-OH in the article. Natural kratom leaf below the threshold is not targeted. As of September 2026, the temporary order for 7-OH itself had not been finalized. Three related substances (mitragynine pseudoindoxyl, MGM-15 and MGM-16) were placed in Schedule I effective August 26, 2026.

Legal status changes quickly. Check the DEA and Federal Register notices for the current order.

Frequently asked questions

Is 7-OH the same as kratom?

No. Kratom leaf contains trace 7-OH. Many 7-OH products on the market are concentrated or chemically converted, and are much stronger.

Does naloxone work on 7-OH?

Treat suspected opioid overdose as an emergency: call 911 and give naloxone if available. Do not wait to see whether it was 7-OH.

Should patients just stop?

Stopping abruptly can cause significant withdrawal and often leads to return to use. Encourage a visit with a clinician who treats OUD.

Can an RN start someone on buprenorphine?

No. RNs assess, monitor, administer ordered medications and support patients. Prescribing needs an authorized prescriber.

This page is educational and is not medical or legal advice. Clinical care for opioid use disorder should follow current guidance and a prescriber's judgment. Laws and enforcement change, so verify with the sources below. CALMN is a 501(c)(3) nonprofit and takes no position on legislation. In an emergency call 911; for crisis support call or text 988.

7-OH and opioid use disorder: what nurses should know